Zhigang Wang

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Emergency Department

Ulcerative Colitis

Replacement Therapy

Top Venues

Therapeutic drug monitoring

CPT: pharmacometrics & systems pharmacology

Clinical and experimental dermatology

Expert review of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Dahham Alsoud, Dirk Jan A R Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray L Barclay, Tomoyuki Mizuno, Iris K Minichmayr, Ron J Keizer, Sebastian Georg Wicha, Gerrit J Wolbink, Jo Lydie Wilfried Lambert, Severine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés-Zamora, Erwin Dreesen
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring 46 (3) (2024)
Dahham Alsoud, Dirk Jan A R Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray L Barclay, Tomoyuki Mizuno, Iris K Minichmayr, Ron J Keizer, Sebastian Georg Wicha, Gerrit J Wolbink, Jo Lydie Wilfried Lambert, Severine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés-Zamora, Erwin Dreesen
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring 46 (3) (2024)
Dahham Alsoud, Dirk Jan A R Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray L Barclay, Tomoyuki Mizuno, Iris K Minichmayr, Ron J Keizer, Sebastian Georg Wicha, Gerrit J Wolbink, Jo Lydie Wilfried Lambert, Severine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés-Zamora, Erwin Dreesen
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring (2024)
Zhigang Wang, Erwin Dreesen
Therapeutic Drug Monitoring 2.0: Time to Assemble the Puzzle. Inflammatory bowel diseases (2023)
Wannee Kantasiripitak, Zhigang Wang, Isabel Spriet, Marc Ferrante, Erwin Dreesen
Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases. Expert review of clinical pharmacology 14 (12) (2022)
Rani Soenen, Zhigang Wang, Lynda Grine, Erwin Dreesen, Lisa Schots, Els Brouwers, Paul J Declerck, Debby Thomas, Jo Lydie Wilfried Lambert
Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis. Clinical and experimental dermatology 47 (7) (2022)
Wannee Kantasiripitak, Marc Ferrante, Sebastian Georg Wicha, Alexander Kensert, Zhigang Wang, João Sabino, Severine Vermeire, Debby Thomas, Marc Ferrante, Erwin Dreesen
Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. CPT: pharmacometrics & systems pharmacology 11 (8) (2022)
Zhigang Wang, Bram Verstockt, João Sabino, Séverine Vermeire, Marc Ferrante, Paul Declerck, Erwin Dreesen
Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease. British journal of clinical pharmacology (2021)
Ruben Faelens, Zhigang Wang, Thomas Bouillon, Paul J Declerck, Marc Ferrante, Séverine Vermeire, Erwin Dreesen
Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis. Pharmaceutics 13 (10) (2021)